These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Glycoform analysis of recombinant and human immunodeficiency virus envelope protein gp120 via higher energy collisional dissociation and spectral-aligning strategy. Yang W; Shah P; Toghi Eshghi S; Yang S; Sun S; Ao M; Rubin A; Jackson JB; Zhang H Anal Chem; 2014 Jul; 86(14):6959-67. PubMed ID: 24941220 [TBL] [Abstract][Full Text] [Related]
23. Structural analysis of the HIV-1 gp120 V3 loop: application to the HIV-Haiti isolates. Andrianov AM; Veresov VG J Biomol Struct Dyn; 2007 Jun; 24(6):597-608. PubMed ID: 17508782 [TBL] [Abstract][Full Text] [Related]
24. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies. Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977 [TBL] [Abstract][Full Text] [Related]
25. Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications. Wang WK; Dudek T; Essex M; Lee TH Proc Natl Acad Sci U S A; 1999 Apr; 96(8):4558-62. PubMed ID: 10200301 [TBL] [Abstract][Full Text] [Related]
26. Range of CD4-Bound Conformations of HIV-1 gp120, as Defined Using Conditional CD4-Induced Antibodies. Kaplan G; Roitburd-Berman A; Lewis GK; Gershoni JM J Virol; 2016 May; 90(9):4481-4493. PubMed ID: 26889042 [TBL] [Abstract][Full Text] [Related]
27. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. Cormier EG; Dragic T J Virol; 2002 Sep; 76(17):8953-7. PubMed ID: 12163614 [TBL] [Abstract][Full Text] [Related]
28. Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation. Shi Y; Brandin E; Vincic E; Jansson M; Blaxhult A; Gyllensten K; Moberg L; Broström C; Fenyö EM; Albert J J Gen Virol; 2005 Dec; 86(Pt 12):3385-3396. PubMed ID: 16298986 [TBL] [Abstract][Full Text] [Related]
30. Structural comparison of a 15 residue peptide from the V3 loop of HIV-1IIIb and an O-glycosylated analogue. Huang X; Smith MC; Berzofsky JA; Barchi JJ FEBS Lett; 1996 Sep; 393(2-3):280-6. PubMed ID: 8814305 [TBL] [Abstract][Full Text] [Related]
31. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120. Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576 [TBL] [Abstract][Full Text] [Related]
32. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage. Verrier F; Borman AM; Brand D; Girard M AIDS Res Hum Retroviruses; 1999 May; 15(8):731-43. PubMed ID: 10357469 [TBL] [Abstract][Full Text] [Related]
33. Characterization of host-cell line specific glycosylation profiles of early transmitted/founder HIV-1 gp120 envelope proteins. Go EP; Liao HX; Alam SM; Hua D; Haynes BF; Desaire H J Proteome Res; 2013 Mar; 12(3):1223-34. PubMed ID: 23339644 [TBL] [Abstract][Full Text] [Related]
34. CCR5 use by human immunodeficiency virus type 1 is associated closely with the gp120 V3 loop N-linked glycosylation site. Clevestig P; Pramanik L; Leitner T; Ehrnst A J Gen Virol; 2006 Mar; 87(Pt 3):607-612. PubMed ID: 16476981 [TBL] [Abstract][Full Text] [Related]
35. Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. Rusert P; Krarup A; Magnus C; Brandenberg OF; Weber J; Ehlert AK; Regoes RR; Günthard HF; Trkola A J Exp Med; 2011 Jul; 208(7):1419-33. PubMed ID: 21646396 [TBL] [Abstract][Full Text] [Related]
36. The influence of N-linked glycans on the molecular dynamics of the HIV-1 gp120 V3 loop. Wood NT; Fadda E; Davis R; Grant OC; Martin JC; Woods RJ; Travers SA PLoS One; 2013; 8(11):e80301. PubMed ID: 24303005 [TBL] [Abstract][Full Text] [Related]
37. Characterization of the tertiary structure of soluble CD4 bound to glycosylated full-length HIVgp120 by chemical modification of arginine residues and mass spectrometric analysis. Hager-Braun C; Tomer KB Biochemistry; 2002 Feb; 41(6):1759-66. PubMed ID: 11827520 [TBL] [Abstract][Full Text] [Related]
38. Mechanism of anti-HIV activity of succinylated human serum albumin. Kuipers ME; vd Berg M; Swart PJ; Laman JD; Meijer DK; Koppelman MH; Huisman H Biochem Pharmacol; 1999 Apr; 57(8):889-98. PubMed ID: 10086322 [TBL] [Abstract][Full Text] [Related]
39. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. McCaffrey RA; Saunders C; Hensel M; Stamatatos L J Virol; 2004 Apr; 78(7):3279-95. PubMed ID: 15016849 [TBL] [Abstract][Full Text] [Related]